Published in Nanomedicine (Lond) on December 01, 2007
Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution. Mol Pharm (2008) 2.94
Pluronic block copolymers: evolution of drug delivery concept from inert nanocarriers to biological response modifiers. J Control Release (2008) 2.63
Effects of nanomaterial physicochemical properties on in vivo toxicity. Adv Drug Deliv Rev (2009) 1.80
Affibody-functionalized gold-silica nanoparticles for Raman molecular imaging of the epidermal growth factor receptor. Small (2011) 1.46
Single-step assembly of homogenous lipid-polymeric and lipid-quantum dot nanoparticles enabled by microfluidic rapid mixing. ACS Nano (2010) 1.35
Cellular response of polyvalent oligonucleotide-gold nanoparticle conjugates. ACS Nano (2010) 1.33
Conscripts of the infinite armada: systemic cancer therapy using nanomaterials. Nat Rev Clin Oncol (2010) 1.30
Design and self-assembly of siRNA-functionalized RNA nanoparticles for use in automated nanomedicine. Nat Protoc (2011) 1.27
Theranostic applications of nanomaterials in cancer: drug delivery, image-guided therapy, and multifunctional platforms. Appl Biochem Biotechnol (2011) 1.22
Fullerenol cytotoxicity in kidney cells is associated with cytoskeleton disruption, autophagic vacuole accumulation, and mitochondrial dysfunction. Toxicol Appl Pharmacol (2010) 1.20
Differential stability of lead sulfide nanoparticles influences biological responses in embryonic zebrafish. Arch Toxicol (2010) 1.16
Molecular simulation of protein-surface interactions: benefits, problems, solutions, and future directions. Biointerphases (2008) 1.14
Evaluation of iron oxide nanoparticle biocompatibility. Int J Nanomedicine (2011) 1.06
In vivo evaluation of safety of nanoporous silicon carriers following single and multiple dose intravenous administrations in mice. Int J Pharm (2010) 1.05
Inhibition of the multidrug resistance P-glycoprotein: time for a change of strategy? Drug Metab Dispos (2014) 1.05
Odyssey of a cancer nanoparticle: from injection site to site of action. Nano Today (2012) 1.04
Nanoparticle size and surface charge determine effects of PAMAM dendrimers on human platelets in vitro. Mol Pharm (2011) 1.01
Toxicological considerations when creating nanoparticle-based drugs and drug delivery systems. Expert Opin Drug Metab Toxicol (2011) 0.98
Cell delivery of therapeutic nanoparticles. Prog Mol Biol Transl Sci (2011) 0.97
Bioconjugated pluronic triblock-copolymer micelle-encapsulated quantum dots for targeted imaging of cancer: in vitro and in vivo studies. Theranostics (2012) 0.97
Techniques for physicochemical characterization of nanomaterials. Biotechnol Adv (2013) 0.96
Determining molecular mass distributions and compositions of functionalized dendrimer nanoparticles. Nanomedicine (Lond) (2009) 0.95
Ambiguities in applying traditional Limulus amebocyte lysate tests to quantify endotoxin in nanoparticle formulations. Nanomedicine (Lond) (2010) 0.95
Mapping the surface adsorption forces of nanomaterials in biological systems. ACS Nano (2011) 0.95
Silver Nanoparticles: Synthesis, Characterization, Properties, Applications, and Therapeutic Approaches. Int J Mol Sci (2016) 0.95
Polymeric micelles, a promising drug delivery system to enhance bioavailability of poorly water-soluble drugs. J Drug Deliv (2013) 0.93
Coaxial electrospray of microparticles and nanoparticles for biomedical applications. Expert Rev Med Devices (2012) 0.90
Automated phenotype recognition for zebrafish embryo based in vivo high throughput toxicity screening of engineered nano-materials. PLoS One (2012) 0.89
Effect of silica and gold nanoparticles on macrophage proliferation, activation markers, cytokine production, and phagocytosis in vitro. Int J Nanomedicine (2014) 0.88
Synthesis, characterization, and evaluation of poly (D,L-lactide-co-glycolide)-based nanoformulation of miRNA-150: potential implications for pancreatic cancer therapy. Int J Nanomedicine (2014) 0.87
Effect of aspect ratio and deformability on nanoparticle extravasation through nanopores. Langmuir (2012) 0.84
Imaging the distribution of individual platinum-based anticancer drug molecules attached to single-wall carbon nanotubes. Nanomedicine (Lond) (2009) 0.83
Innovative pharmaceutical development based on unique properties of nanoscale delivery formulation. Nanoscale (2013) 0.82
Self-associated submicron IgG1 particles for pulmonary delivery: effects of non-ionic surfactants on size, shape, stability, and aerosol performance. AAPS PharmSciTech (2012) 0.82
Reversion of pH-induced physiological drug resistance: a novel function of copolymeric nanoparticles. PLoS One (2011) 0.81
Nanoparticle based insulin delivery system: the next generation efficient therapy for Type 1 diabetes. J Nanobiotechnology (2015) 0.79
Avoiding drying-artifacts in transmission electron microscopy: Characterizing the size and colloidal state of nanoparticles. Sci Rep (2015) 0.79
Release kinetics of paclitaxel and cisplatin from two and three layered gold nanoparticles. Eur J Pharm Biopharm (2015) 0.79
Value of phagocyte function screening for immunotoxicity of nanoparticles in vivo. Int J Nanomedicine (2015) 0.78
Cell death pathway induced by resveratrol-bovine serum albumin nanoparticles in a human ovarian cell line. Oncol Lett (2015) 0.77
Nanostructures Enabled by On-Wire Lithography (OWL). Chem Phys Lett (2010) 0.76
Fibrillous carbon nanotube: an unexpected journey. Crit Rev Oncog (2014) 0.76
Microfluidic preparation of polymer nanospheres. J Nanopart Res (2014) 0.75
Recommendations for Benchmarking Preclinical Studies of Nanomedicines. Cancer Res (2015) 0.75
Methods for the In Vitro Characterization of Nanomedicines-Biological Component Interaction. J Pers Med (2017) 0.75
The evolving landscape of drug products containing nanomaterials in the United States. Nat Nanotechnol (2017) 0.75
Physicochemical characterization of drug nanocarriers. Int J Nanomedicine (2017) 0.75
A comparative study of the adhesion of biosynthesized gold and conjugated gold/prodigiosin nanoparticles to triple negative breast cancer cells. J Mater Sci Mater Med (2017) 0.75
Immunological properties of engineered nanomaterials. Nat Nanotechnol (2007) 5.59
Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science (2013) 5.09
Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy. Adv Drug Deliv Rev (2009) 3.08
Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution. Mol Pharm (2008) 2.94
Nanotechnology safety concerns revisited. Toxicol Sci (2007) 2.41
Design and function of a dendrimer-based therapeutic nanodevice targeted to tumor cells through the folate receptor. Pharm Res (2002) 2.30
Interaction of colloidal gold nanoparticles with human blood: effects on particle size and analysis of plasma protein binding profiles. Nanomedicine (2008) 1.99
Nanoparticles and the immune system. Endocrinology (2009) 1.79
Lipid bilayer disruption by polycationic polymers: the roles of size and chemical functional group. Langmuir (2005) 1.56
Detoxification of gold nanorods by treatment with polystyrenesulfonate. ACS Nano (2008) 1.42
HER2 specific tumor targeting with dendrimer conjugated anti-HER2 mAb. Bioconjug Chem (2006) 1.36
Common pitfalls in nanotechnology: lessons learned from NCI's Nanotechnology Characterization Laboratory. Integr Biol (Camb) (2013) 1.30
Nanomaterial standards for efficacy and toxicity assessment. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2010) 1.30
Targeted gadolinium-loaded dendrimer nanoparticles for tumor-specific magnetic resonance contrast enhancement. Int J Nanomedicine (2008) 1.28
Design and self-assembly of siRNA-functionalized RNA nanoparticles for use in automated nanomedicine. Nat Protoc (2011) 1.27
Best practices in cancer nanotechnology: perspective from NCI nanotechnology alliance. Clin Cancer Res (2012) 1.24
Rapid distribution of liposomal short-chain ceramide in vitro and in vivo. Drug Metab Dispos (2008) 1.24
Induction of autophagy in porcine kidney cells by quantum dots: a common cellular response to nanomaterials? Toxicol Sci (2008) 1.23
Fullerenol cytotoxicity in kidney cells is associated with cytoskeleton disruption, autophagic vacuole accumulation, and mitochondrial dysfunction. Toxicol Appl Pharmacol (2010) 1.20
Method for analysis of nanoparticle hemolytic properties in vitro. Nano Lett (2008) 1.20
In vitro targeting of synthesized antibody-conjugated dendrimer nanoparticles. Biomacromolecules (2004) 1.13
A novel nanoparticulate formulation of arsenic trioxide with enhanced therapeutic efficacy in a murine model of breast cancer. Clin Cancer Res (2010) 1.12
Translational considerations for cancer nanomedicine. J Control Release (2010) 1.12
Lack of significant dermal penetration of titanium dioxide from sunscreen formulations containing nano- and submicron-size TiO2 particles. Toxicol Sci (2010) 1.11
Zeta potential measurement. Methods Mol Biol (2011) 1.10
HER2-specific affibody-conjugated thermosensitive liposomes (Affisomes) for improved delivery of anticancer agents. J Liposome Res (2008) 1.05
Nanoparticle size and surface charge determine effects of PAMAM dendrimers on human platelets in vitro. Mol Pharm (2011) 1.01
Adverse effects of fullerenes on endothelial cells: fullerenol C60(OH)24 induced tissue factor and ICAM-I membrane expression and apoptosis in vitro. Int J Nanomedicine (2008) 0.97
Identification and avoidance of potential artifacts and misinterpretations in nanomaterial ecotoxicity measurements. Environ Sci Technol (2014) 0.95
Ambiguities in applying traditional Limulus amebocyte lysate tests to quantify endotoxin in nanoparticle formulations. Nanomedicine (Lond) (2010) 0.95
Detection and analysis of tumor fluorescence using a two-photon optical fiber probe. Biophys J (2004) 0.93
Prediction of nanoparticle prodrug metabolism by pharmacokinetic modeling of biliary excretion. J Control Release (2013) 0.93
Dendrimer-based BH3 conjugate that targets human carcinoma cells. Biomacromolecules (2007) 0.92
Detection and quantitative evaluation of endotoxin contamination in nanoparticle formulations by LAL-based assays. Methods Mol Biol (2011) 0.92
Nanoparticles and the blood coagulation system. Part II: safety concerns. Nanomedicine (Lond) (2013) 0.90
Activation of the MAP kinase cascade by exogenous calcium-sensing receptor. Mol Cell Endocrinol (2003) 0.89
Challenges and opportunities in the advancement of nanomedicines. J Control Release (2012) 0.89
Macrophage scavenger receptor A mediates the uptake of gold colloids by macrophages in vitro. Nanomedicine (Lond) (2011) 0.89
SEM X-ray microanalysis of nanoparticles present in tissue or cultured cell thin sections. Methods Mol Biol (2011) 0.88
Nanomedicines: addressing the scientific and regulatory gap. Ann N Y Acad Sci (2014) 0.88
Triggering of RNA interference with RNA-RNA, RNA-DNA, and DNA-RNA nanoparticles. ACS Nano (2014) 0.88
Understanding the correlation between in vitro and in vivo immunotoxicity tests for nanomedicines. J Control Release (2013) 0.87
Dendrimer-induced leukocyte procoagulant activity depends on particle size and surface charge. Nanomedicine (Lond) (2011) 0.87
Assessing the barriers to image-guided drug delivery. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2013) 0.86
Molecular heterogeneity analysis of poly(amidoamine) dendrimer-based mono- and multifunctional nanodevices by capillary electrophoresis. Analyst (2006) 0.86
Biological assessment of triazine dendrimer: toxicological profiles, solution behavior, biodistribution, drug release and efficacy in a PEGylated, paclitaxel construct. Mol Pharm (2010) 0.86
Biotargeted nanomedicines for cancer: six tenets before you begin. Nanomedicine (Lond) (2013) 0.85
Analysis of poly(amidoamine)-succinamic acid dendrimers by slab-gel electrophoresis and capillary zone electrophoresis. Electrophoresis (2005) 0.85
Strategy for selecting nanotechnology carriers to overcome immunological and hematological toxicities challenging clinical translation of nucleic acid-based therapeutics. Expert Opin Drug Deliv (2015) 0.83
Nanoparticles and the blood coagulation system. Part I: benefits of nanotechnology. Nanomedicine (Lond) (2013) 0.82
Biological tissue and cell culture specimen preparation for TEM nanoparticle characterization. Methods Mol Biol (2011) 0.82
Quantitative characterization of quantum dot-labeled lambda phage for Escherichia coli detection. Biotechnol Bioeng (2009) 0.82
A novel gadolinium-based trimetasphere metallofullerene for application as a magnetic resonance imaging contrast agent. Invest Radiol (2013) 0.81
In vitro analysis of nanoparticle uptake by macrophages using chemiluminescence. Methods Mol Biol (2011) 0.81
Qualitative analysis of total complement activation by nanoparticles. Methods Mol Biol (2011) 0.81
Choice of method for endotoxin detection depends on nanoformulation. Nanomedicine (Lond) (2013) 0.80
Synergistic combination therapy with nanoliposomal C6-ceramide and vinblastine is associated with autophagy dysfunction in hepatocarcinoma and colorectal cancer models. Cancer Lett (2013) 0.80
Inhibition of phosphoinositol 3 kinase contributes to nanoparticle-mediated exaggeration of endotoxin-induced leukocyte procoagulant activity. Nanomedicine (Lond) (2013) 0.80
Detecting and measuring free gadolinium in nanoparticles for MRI imaging. Methods Mol Biol (2011) 0.80
Polymeric curcumin nanoparticle pharmacokinetics and metabolism in bile duct cannulated rats. Mol Pharm (2013) 0.79
Gold nanoparticle quantitation via fluorescence in solution and cell culture. Methods Mol Biol (2011) 0.79
Immunological and hematological toxicities challenging clinical translation of nucleic acid-based therapeutics. Expert Opin Biol Ther (2015) 0.78
Chromatographic methods for the quantification of free and chelated gadolinium species in MRI contrast agent formulations. Anal Bioanal Chem (2010) 0.78
Biological applications of dendrimers. Mol Pharm (2012) 0.78
Method for analysis of nanoparticle hemolytic properties in vitro. Methods Mol Biol (2011) 0.77
Biodistribution of nanomedicines. Mol Pharm (2008) 0.76
Method for in vitro analysis of nanoparticle thrombogenic properties. Methods Mol Biol (2011) 0.76
Analysis of fullerene-based nanomaterial in serum matrix by CE. Electrophoresis (2007) 0.75
A novel cell-based system for the rapid quantitative evaluation of (anti)-inflammatory potential of test substances. J Immunol Methods (2003) 0.75
Lipid component quantitation by thin layer chromatography. Methods Mol Biol (2011) 0.75
Method for analysis of nanoparticle effects on cellular chemotaxis. Methods Mol Biol (2011) 0.75
Newkome-type dendron stabilized gold nanoparticles: Synthesis, reactivity, and stability. Chem Mater (2011) 0.75
Characterization of nanoparticles by matrix assisted laser desorption ionization time-of-flight mass spectrometry. Methods Mol Biol (2011) 0.75
Application of a Scavenger Receptor A1 Targeted Polymeric Prodrug Platform for Lymphatic Drug Delivery in HIV. Mol Pharm (2020) 0.75
Quantitative analysis of PEG-functionalized colloidal gold nanoparticles using charged aerosol detection. Anal Bioanal Chem (2015) 0.75
Analysis of microbial contamination in nanoparticle formulations. Methods Mol Biol (2011) 0.75